Crohn’s disease is a chronic, immune-mediated inflammatory bowel disease that can affect any part of the gastrointestinal tract, most often the terminal ileum and colon. It causes patchy, full-thickness inflammation, so complications such as strictures, fistulas, abscesses, malnutrition, and perianal disease may occur.
I can teach it using textbook concepts and frame it like a research-paper review. We can cover:
Current guidance increasingly favors early effective therapy for moderate-to-severe or high-risk disease, objective monitoring of inflammation rather than symptoms alone, and avoiding long-term corticosteroids. The newer therapy landscape includes anti-TNF drugs, vedolizumab, ustekinumab, IL-23 pathway therapies, and JAK inhibition, selected according to disease phenotype, prior treatments, safety factors, and patient priorities. The
AGA update announcement describes this shift toward earlier high-efficacy treatment.